CEP72

Across TCGA pan-cancer cohorts, CEP72 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CEP72 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CEP72 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP72 expression acts as an unfavorable survival marker.

HNSC, PRAD, and BLCA are the cancer types where CEP72 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.162	0.639	.030	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	0.228	0.684	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CEP72–HNSC (OS)

Open the HNSC breakdown →